Covid-19 Pandemic and Possible Links with Mthfr Mutations, Homocysteinemia, and Metabolic Disturbances: Short Review

Coronovirus-19 (COVID-19) is an associate degree infection caused by the SARS-CoV-2 virus inflicting a worldwide pandemic and chiefly characterized by respiratory symptoms, many times accompanied by a cytokine storm. It causes migration of the neutrophils, macrophages and inflammatory cytokines resulting in the destruction of the alveolar-capillary walls. Coagulopathy in patients with COVID-19 may be a common complication that jeopardizes the clinical course and is related to poorer outcomes and probable death. The methylenetetrahydrofolate enzyme (MTHFR) is coded by the gene with the image MTHFR on chromosome one location p36.3 in humans, and there are desoxyribonucleic acid sequence variants (genetic polymorphisms) related to this gene. However, the 2 commonest ones are C677T and A1298C. Deficiencies within the production of this accelerator are related to raise risk of cardiac muscle infarctions, stroke, thrombosis, and several conditions. Homocysteine (Hcy) is a chemical in the blood formed when the amino acid methionine, a building block of the proteins, is naturally metabolized to be excreted in the urine; throughout this breakdown method, our body will recycle homocysteine to be reused to make different proteins. For this utilization, we need vitamins B12, B6, and folate. Also, for utilization to be the foremost economical, the accelerator MTHFR is needed. Transmissible mutations within the factor that create the MTHFR accelerator will result in an associate degree accelerator that’s not optimally active and should result in elevated homocysteine levels. Several medical conditions, like vascular disorders, obesity, diabetic disorder, peripheral neuropathy, and thrombophilia’s inside others, are associated with high Hcy levels and MTHFR mutations. Few reports link the high risk and poor prognosis with COVID-19 with MTHFR mutation and metabolic disorders like obesity and Diabetes mellitus. In this this review, we provide recommendations to prevent complications in patients with COVID, MTHFR mutations, Diabetes, and Obesity.

Valós idejű polimeráz láncreakció alkalmazása cytomegalovirus-fertőzés és -reaktiváció nyomon követésére malignus hematológiai betegségek kemoterápiás kezelése során és autológ őssejt-transzplantációt követően

Introduction: Because of the use of chemo-immunotherapeutic drugs, cytomegalovirus infection is one of the most important infectious complications among patients with haematological malignancies. Aim: The aim of the authors was to detect cytomegalovirus infection and reactivation using quantitative real-time polymerase chain reaction. Method: Between 2012 and 2014, the authors retrospectively analysed 96 patient’s medical history hospitalised in haematology Unit. Patients were grouped on the basis of their underlying diseases (lymphoprolipherative malignancies, acute leukaemias), and the following groups were created: autologous stem cell transplanted and non-transplanted groups. Results: Eighty-three patients were treated with lymphoprolipherative disorders, and 63 (76%) of them underwent autologous stem cell transplantation. Out of the 604 plasma specimens 46 (7.6%) were positive for the cytomegalovirus desoxyribonucleic acid collected from 25 patients [6 non-transplanted (18%) and 19 from the transplanted group (30.2%)]. The frequency of cytomegalovirus positivity was doubled in the transplanted patient group, however, reactivation was asymptomatic in 68% of the cases. Conclusions: The routine use of cytomegalovirus monitoring is not necessary in this patient group. In case of suspected cytomegalovirus infection, molecular tests allow early preemptive antiviral therapy, which may decrease the mortality attributed to cytomegalovirus infection. Orv. Hetil., 2016, 157(35), 1403–1409.